Fundraising Fox

Mirador Therapeutics

San Diego, US · Founded 2023 · 3 known investors

miradortx.com ↗

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach. The company targets therapeutics to improve treatment efficacy beyond current standards in immunology and fibrotic conditions.

AI & Machine LearningHealthtechMedical Devicesin /mirador-therapeutics

Founders & leadership

PB
Paul BernsDirector
JP
Joseph PapaDirector
MC
Mark C. McKennaExecutive Officer, Director
SG
Scott GlennDirector
KB
Kristina BurowDirector
VB
Vika BroughExecutive Officer
DB
David Bonita, M.D.Director
TK
Timothy K. AndrewsExecutive Officer

Investors · 3

ARCH Venture PartnersChicago · $50K – $250M
OrbiMedNew York · $1M – $75M
Sanofi VenturesCambridge · $5M

Reported raises · per SEC filings

Form D private placements
▶$80MraisedApr 2024 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul BernsDirector
  • Joseph PapaDirector
  • Mark C. McKennaExecutive Officer, Director
  • Scott GlennDirector
  • Kristina BurowDirector
  • Vika BroughExecutive Officer
  • David Bonita, M.D.Director
  • Timothy K. AndrewsExecutive Officer
Offering amount
$80M
Amount sold
$80M
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$333MraisedApr 2024 · 31 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul BernsDirector
  • Timothy K. AndrewsExecutive Officer
  • David Bonita, M.D.Director
  • Mark C. McKennaExecutive Officer, Director
  • Scott GlennDirector
  • Kristina BurowDirector
  • Vika BroughExecutive Officer
  • Joseph PapaDirector
Offering amount
$333M
Amount sold
$333M
First sale
Feb 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news